retatrutide trial results 🚨 TRIUMPH-1 Phase 3 top-line results, much awaited and just announced ⬇️ 28.3% Weight loss at 80 weeks ⬇️ 30.3% weight loss at 104 weeks among adults with baseline BMI >35 The experimental GLP-1 drug 'reta'

Since control of diabetes and obesity are significant health outcome risk factors, it is conceivable that the shortages and high cost of GLP1 agonists will exacerbate existing health disparities. David Cutler, MD His perspective echoed what Ma told us, namely that [o]ne of the biggest bottlenecks with GLP-1RA access is cost and insurance. Even if a doctor prescribes [this type of drug], patients cannot obtain it if their insurance does not cover it, which could worsen disparities, especially for those with public insurance or in underserved populations, he also emphasized

For a compounded GLP-1 telehealth subscription, that is a mistake

Polycystic Ovary Syndrome: Assessment and Management

Dosing optimization represents a critical prevention strategy, as higher doses and prolonged exposure periods appear associated with increased allodynia risk

Short-term storage at 4C is acceptable when use is imminent

How Much Protein Should You Eat With Your Calories